GLUT1, GLUT3, and MCT1 expression levels decreased in the general group of T2DM patients (Table 2), and this decrease was especially significant when the control or recently diagnosed patients were compared to successfully managed patients or to patients with disease-related complications (see Table 3, Figs. 1 and 3). Here, SLC16A1 is linked to type 2 diabetes mellitus.